Neurocrine Biosciences (NBIX) Competitors $140.40 +4.29 (+3.15%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$139.16 -1.25 (-0.89%) As of 09/4/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. BIIB, INCY, UTHR, BMRN, EXEL, MDGL, EXAS, HALO, RGEN, and IONSShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Biogen Incyte United Therapeutics BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Exact Sciences Halozyme Therapeutics Repligen Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Is BIIB or NBIX more profitable? Biogen has a net margin of 15.31% compared to Neurocrine Biosciences' net margin of 13.88%. Biogen's return on equity of 13.85% beat Neurocrine Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Neurocrine Biosciences 13.88%13.22%9.39% Does the media favor BIIB or NBIX? In the previous week, Biogen had 26 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 46 mentions for Biogen and 20 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.41 beat Biogen's score of 1.07 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 28 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 16 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, BIIB or NBIX? Biogen has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Which has preferable earnings and valuation, BIIB or NBIX? Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.12$1.63B$10.4613.38Neurocrine Biosciences$2.36B5.91$341.30M$3.3841.54 Do institutionals & insiders have more ownership in BIIB or NBIX? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts recommend BIIB or NBIX? Biogen currently has a consensus price target of $185.74, suggesting a potential upside of 32.73%. Neurocrine Biosciences has a consensus price target of $159.50, suggesting a potential upside of 13.60%. Given Biogen's higher probable upside, research analysts clearly believe Biogen is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.86 SummaryNeurocrine Biosciences beats Biogen on 9 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.50B$2.55B$5.76B$9.85BDividend YieldN/A49.35%6.67%4.51%P/E Ratio41.5422.9075.9926.43Price / Sales5.91714.55546.94119.09Price / Cash40.27169.7737.0558.92Price / Book5.495.3910.916.06Net Income$341.30M$32.95M$3.29B$266.28M7 Day Performance0.57%1.08%0.18%-0.32%1 Month Performance9.35%6.32%6.26%3.44%1 Year Performance15.83%-0.28%51.54%23.11% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8616 of 5 stars$140.40+3.2%$159.50+13.6%+14.6%$13.50B$2.36B41.541,800Positive NewsShort Interest ↑BIIBBiogen4.8466 of 5 stars$136.36-2.1%$185.74+36.2%-31.7%$19.99B$10.00B13.047,605Trending NewsAnalyst ForecastINCYIncyte4.6615 of 5 stars$84.76-0.3%$81.60-3.7%+32.8%$16.55B$4.24B19.262,617Positive NewsAnalyst ForecastShort Interest ↑UTHRUnited Therapeutics4.7218 of 5 stars$305.38-2.2%$382.00+25.1%+7.7%$13.77B$3.08B11.921,305Trending NewsAnalyst ForecastInsider TradeShort Interest ↑BMRNBioMarin Pharmaceutical4.992 of 5 stars$58.50-0.1%$93.17+59.3%-36.8%$11.23B$2.85B17.363,040Positive NewsAnalyst ForecastEXELExelixis4.8174 of 5 stars$37.90-1.9%$44.06+16.2%+46.0%$10.20B$2.17B18.221,147MDGLMadrigal Pharmaceuticals4.1593 of 5 stars$412.23-0.6%$445.71+8.1%+75.8%$9.15B$515.55M-32.0890Positive NewsAnalyst ForecastEXASExact Sciences4.8341 of 5 stars$45.66-3.8%$67.43+47.7%-10.0%$8.64B$2.94B-8.417,000Positive NewsShort Interest ↑HALOHalozyme Therapeutics4.6845 of 5 stars$72.21+0.5%$67.11-7.1%+18.1%$8.45B$1.18B16.52390Trending NewsAnalyst UpgradeInsider TradeAnalyst RevisionRGENRepligen4.8588 of 5 stars$121.26-2.8%$169.45+39.7%-16.5%$6.82B$634.44M-485.021,778Positive NewsAnalyst ForecastIONSIonis Pharmaceuticals4.1944 of 5 stars$41.82-2.0%$60.92+45.7%+24.6%$6.67B$705M-22.731,069Trending NewsAnalyst ForecastInsider Trade Related Companies and Tools Related Companies Biogen Competitors Incyte Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Madrigal Pharmaceuticals Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Ionis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NBIX Stock Alerts